Victory Capital Management
KPTI icon

Victory Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Victory Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-966
Closed -$12K – 2506
2024
Q3 		$12K Buy
966
+33
+4% +$410 ﹤0.01% 2468
2024
Q2 		$12.1K Buy
+933
New +$15.4K ﹤0.01% 2459
2023
Q4 		– Sell
-762
Closed -$15.3K – 2585
2023
Q3 		$15.3K Buy
762
+1
+0.1% +$22 ﹤0.01% 2464
2023
Q2 		$20.4K Sell
761
-18
-2% -$775 ﹤0.01% 2447
2023
Q1 		$45.5K Buy
+779
New +$38.5K ﹤0.01% 2452
2022
Q2 		– Sell
-13,171
Closed -$1.46M – 2726
2022
Q1 		$1.46M Buy
+13,171
New +$1.64M ﹤0.01% 1621
2021
Q2 		– Sell
-762
Closed -$120K – 2789
2021
Q1 		$120K Buy
+762
New +$161K ﹤0.01% 2579

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Victory Capital Management's KPTI Position: Q4 2024 in Review

Victory Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 966 shares — an estimated $12K sold.

Victory Capital Management first reported a position in KPTI in Q1 2021 and held it in 7 quarters. The position peaked at $1.46M in Q1 2022. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

  • Victory Capital Management reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Victory Capital Management sold 966 Karyopharm Therapeutics shares in Q4 2024, an estimated $12K.
  • Victory Capital Management first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 7 quarters.
  • Victory Capital Management's Karyopharm Therapeutics position peaked at $1.46M in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Victory Capital Management's 13F filing for Q4 2024, filed 6 Feb 2025.